Allogeneic CAR T-cell therapy has the potential to address a number of shortcomings inherent in autologous CAR-T therapy in order to maximize potential CAR-T recipients and optimize patient outcomes. Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO, discusses the first-in-human data of ALLO-501A, an allogeneic CAR-T product under investigation in relapsed/refractory (R/R) large B-cell lymphoma in the ALPHA2 study (NCT04416984). ALLO-501A is engineered to reduce the risk of graft versus host disease and permit the use of an anti-CD42 monoclonal antibody (ALLO-647) for lymphodepletion. 11 patients were enrolled in the dose escalation cohort and preliminary data suggest an acceptable safety profile following ALLO-501A and ALLO-647 and early signs of efficacy in large B-cell lymphoma. Enrollment is ongoing. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.